TY - JOUR
T1 - Correlates and Consequences of High Serum Irisin Concentration in Patients on Hemodialysis
T2 - A Longitudinal Analysis
AU - Chiang, Janet M.
AU - Delgado, Cynthia
AU - Kaysen, George A.
AU - Segal, Mark R.
AU - Chertow, Glenn M.
AU - Johansen, Kirsten L.
N1 - Funding Information:
Support: This work was supported by funding from the National Institutes for Diabetes and Digestive and Kidney Diseases (NIDDK) to Dr. Johansen ( R01 DK107269 and K24 DK085153 ) and to the UCSF Endocrinology and Metabolism Fellowship ( 5T32DK007418-37 ). Dr. Chiang's work was supported in part by the Department of Veterans Affairs fellowship, as well as the Wilsey Family Clinical Fellowships in Diabetes and Endocrinology. Dr. Delgado's work was supported by the Department of Veterans Affairs , Clinical Science Research and Development Program under Career Development Award 1IK2CX000527. The NIDDK, Department of Veterans Affairs, and Wilsey Family did not have any role in study design, collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. The authors do not have financial relationships with entities that might reasonably be considered to be relevant stakeholders. There are no other disclosures that may reasonably represent or create perception of a conflict of interest related to the submitted work.
PY - 2020
Y1 - 2020
N2 - Objective: Irisin is a hormone released by muscle in response to exercise that acts on white adipose cells to stimulate browning of adipose tissue. We aimed to examine irisin correlates and consequences of irisin in patients receiving hemodialysis. Design and Methods: A prospective cohort study was conducted using data from 749 prevalent patients receiving hemodialysis. Multivariable linear regression and multivariable generalized estimating equations were used to determine correlates of baseline and change in serum irisin concentration. Proportional hazards (Cox) regression was used to assess the association between serum irisin concentration and time to death. Results: Age and body mass index were inversely associated with baseline and change in serum irisin concentration. Lower muscle mass as estimated by serum creatinine concentration was associated with lower irisin concentration (−1.38% per mg/dL (95% confidence interval [CI]: −2.45, −0.21) and with a 0.72% decrease in irisin concentration (95% CI: −1.48, −0.04) from baseline to 12 months. Each 50% higher serum interleukin-6 (IL-6) concentration was associated with 1.52% higher serum irisin concentration (95% CI: 0.38, 2.66) at baseline and an increase of 1.04% in irisin concentration over 1 year (95% CI: 0.47, 1.61). Irisin concentration at baseline was associated with higher hazard of death (hazards ratio: 1.45, 95% CI: 1.05 2.00); an increase in irisin concentration over 1 year was associated with a higher hazard of death (hazards ratio: 1.34, 95% CI: 1.01, 1.79). In formal mediation analysis, serum IL-6 was a mediator in the association between serum irisin and mortality. Conclusions: Lower serum creatinine (reflecting lower muscle mass) and higher serum IL-6 were associated with higher serum irisin concentrations. Higher serum irisin concentrations were associated with higher mortality, which may be mediated by inflammation.
AB - Objective: Irisin is a hormone released by muscle in response to exercise that acts on white adipose cells to stimulate browning of adipose tissue. We aimed to examine irisin correlates and consequences of irisin in patients receiving hemodialysis. Design and Methods: A prospective cohort study was conducted using data from 749 prevalent patients receiving hemodialysis. Multivariable linear regression and multivariable generalized estimating equations were used to determine correlates of baseline and change in serum irisin concentration. Proportional hazards (Cox) regression was used to assess the association between serum irisin concentration and time to death. Results: Age and body mass index were inversely associated with baseline and change in serum irisin concentration. Lower muscle mass as estimated by serum creatinine concentration was associated with lower irisin concentration (−1.38% per mg/dL (95% confidence interval [CI]: −2.45, −0.21) and with a 0.72% decrease in irisin concentration (95% CI: −1.48, −0.04) from baseline to 12 months. Each 50% higher serum interleukin-6 (IL-6) concentration was associated with 1.52% higher serum irisin concentration (95% CI: 0.38, 2.66) at baseline and an increase of 1.04% in irisin concentration over 1 year (95% CI: 0.47, 1.61). Irisin concentration at baseline was associated with higher hazard of death (hazards ratio: 1.45, 95% CI: 1.05 2.00); an increase in irisin concentration over 1 year was associated with a higher hazard of death (hazards ratio: 1.34, 95% CI: 1.01, 1.79). In formal mediation analysis, serum IL-6 was a mediator in the association between serum irisin and mortality. Conclusions: Lower serum creatinine (reflecting lower muscle mass) and higher serum IL-6 were associated with higher serum irisin concentrations. Higher serum irisin concentrations were associated with higher mortality, which may be mediated by inflammation.
UR - http://www.scopus.com/inward/record.url?scp=85097061574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097061574&partnerID=8YFLogxK
U2 - 10.1053/j.jrn.2020.05.005
DO - 10.1053/j.jrn.2020.05.005
M3 - Article
AN - SCOPUS:85097061574
JO - Journal of Renal Nutrition
JF - Journal of Renal Nutrition
SN - 1051-2276
ER -